{
    "name": "Factor IX, recombinant/albumin fusion protein",
    "comment": "Rx",
    "other_names": [
        "Idelvion"
    ],
    "classes": [
        "Coagulation Factors",
        "Hemostatics"
    ],
    "source": "https://reference.medscape.com/drug/idelvion-factor-ix-recombinant-albumin-fusion-protein-1000090",
    "pregnancy": {
        "common": [
            "No data exist regarding use in pregnant women to inform on drug-associated risk",
            "Animal reproduction studies have not been conducted",
            "Should be given to a pregnant woman only if clearly needed"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Life-threatening hypersensitivity reactions to the drug or its components, including hamster proteins"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions, including anaphylaxis, are possible; if hypersensitivity symptoms occur, immediately discontinue administration and initiate appropriate treatment (see Contraindications)",
                "Formation of neutralizing antibodies to Factor IX may occur",
                "Thromboembolism (eg, pulmonary embolism, venous thrombosis, arterial thrombosis) may occur when using Factor IX-containing products",
                "Nephrotic syndrome reported following attempted immune tolerance induction in hemophilia B patients who develop",
                "Patients with Factor IX inhibitors and a history of allergic reactions",
                "Monitor Factor IX plasma levels and development of inhibitors"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "1.8"
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Eczema",
            "percent": null
        }
    ]
}